Overview

A Phase II, Randomised Clinical Trial of Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Ev

Status:
NOT_YET_RECRUITING

Trial end date:
2037-09-01

Target enrollment:

Participant gender:

Summary

This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.

Phase:

PHASE2

Details

Lead Sponsor:

Melanoma Institute Australia

Treatments:

Ipilimumab
Nivolumab
relatlimab